SAB-185

About SAB Biotherapeutics

SAB Biotherapeutics' mission is to leverage its proprietary DiversitAb™ platform to develop a new class of fully human polyclonal antibody therapeutics. Its key achievement is the creation of a validated, scalable production system using transgenic cattle, which has advanced multiple candidates into clinical trials, including a program for COVID-19. The company's strategy is to clinically validate its platform in autoimmune disease, starting with type 1 diabetes, and expand into other areas of high unmet need where polyclonal antibodies offer a differentiated therapeutic profile. As a public company, SAB is focused on executing its clinical milestones to demonstrate proof-of-concept and attract strategic partnerships.

Therapeutic Areas

Other COVID-19 (SARS-CoV-2) Drugs